With the FDA recently approving acoramidis for ATTR cardiac amyloidosis, how should we decide on optimal drug therapy and options for our patients?

Both tafamidis and acoramidis are stabilizers of transthyretin (TTR) and both have been shown in clinical trials to lessen hospital admissions for CHF and to reduce death in TTR cardiomyopathy compared to placebo. Although acoramidis is said to produce "near complete stabilization" of TTR, and is re...